The Effects of Maternal Metformin Treatment on Late Prenatal and Early Postnatal Development of the Offspring Are Modulated by Sex

• Main Authors: Consolacion Garcia-Contreras, Marta Vazquez-Gomez, José Luis Pesantez-Pacheco, Ana Heras-Molina, Teresa Encinas, Susana Astiz, Antonio Gonzalez-Bulnes
• Format: Article
• Language: English
• Published: MDPI AG 2020-11-01
• Series: Pharmaceuticals
• Subjects: intrauterine growth restriction; metformin; pregnancy; swine model
• Online Access: https://www.mdpi.com/1424-8247/13/11/363

Metformin is currently used to improve pregnancy outcome in women affected by polycystic ovary syndrome (PCOS) or diabetes. However, metformin may also be useful in pregnancies at risk of intrauterine growth restriction (IUGR) since it improves placental efficiency and the fetuses’ developmental competence. There is no data on the duration of the effect of this treatment from the prenatal up to the postnatal stages. Therefore, the present trial aimed at determining the impact of metformin treatment on the offspring neonatal traits and early postnatal development (i.e., during lactation) using an in vivo swine model. The results support that maternal metformin treatment during pregnancy induces protective changes in body shape and composition of the progeny (i.e., larger head size and body length at birth and higher total viscera weight at weaning). However, there were also major effects of the offspring sex (smaller corpulence in females and lower relative weight of main viscerae in males), which should be considered for further preclinical studies and when even the current clinical application in women affected by PCOS or diabetes is implemented.